BofA Upgrades Candel Therapeutics to Buy as Prostate Cancer Filing Nears Prostate data look filing-ready, cash is $201.6M, and analysts see ~66% upside. Credit: Candel Therapeutics Subscribe now Already have an account? Sign in.
